Vaccine comes to the rescue to treat SARS-like syndrome, ADEM and other coronaviruses

The Food and Drug Administration (FDA) has announced the approval of Coronavirus Booster Shots for adults. These four doses of SebiVax, an investigational antiviral therapy designed to treat advanced SARS-like syndrome and acute disseminated encephalomyelitis (ADEM), were developed by FDA-registered biotechnology company Viagen Inc. to address an ongoing global health need. These shots are the second-ever human vaccine to treat systemic infections from Coronavirus E104, SARS-1, RSV-A, and human coronavirus.

These shots are important since the current, recommended clinical practice of treating severe SARS-like syndrome and ADEM is not with antiviral therapies, despite the fact that these infections are a serious concern worldwide. There is significant unmet medical need with respect to all systemic infections from SARS-1 and that is why the development of the epinephrine booster shot for adults, SebiVax, is valuable.

These vaccines have been successfully tested in animals in laboratory and clinical settings. In humans, SebiVax produced high antibody titers, like a good booster shot, within three hours after vaccination. Another important component of SebiVax is its history of safety. SebiVax has been developed with extensive testing on the healthy and immunocompromised community, and the safety profile is substantial. These included: no cases of immune suppression after booster shots and no C.v. infections reported during early human clinical trial experiences.

“We’re excited to help serve patients in the urgent need for an alternative therapy for devastating SARS-like syndrome and severe ADEM infections,” said Eric Gaillard, Chief Commercial Officer, Viagen Inc. “Viagen is the world’s leader in developing new biotherapeutic vaccines to treat serious infectious diseases. We’re grateful to FDA for their approval of SebiVax, which has the potential to save the lives of a number of people suffering from SARS-like syndrome and ADEM, and we are now developing this treatment option for use in the E. coli Outbreak that occurred in the United States in 2017.”

Viagen Inc. is a biotechnology company dedicated to the development of next-generation vaccines to help save lives. It is listed on Nasdaq Global Market under the symbol “SVEN.”

Read more about SARS-1, Flu-A and other coronaviruses.

Leave a Comment